Altimmune vs Lyell Immunopharma
Altimmune and Lyell Immunopharma are similar in size: $41,000 and $36,000 of revenue in their latest fiscal years. Altimmune grew faster (105.0% against -41.0%). Altimmune kept more of each dollar of sales as profit: a net margin of -214861.0% against -762355.6%.
| Latest fiscal year | AltimmuneALT, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $41,000 | $36,000 |
| Revenue growth | 105.0% | -41.0% |
| Net income | −$88.1m | −$274m |
| Operating margin | — | -748344.4% |
| Net margin | -214861.0% | -762355.6% |
| Return on equity | -50.6% | -87.0% |
| Free cash flow | −$67.5m | −$151m |
| Cash | $43.8m | $60.2m |
| Total debt | $35.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 57 | 161 |
| Market value | $398m | $252m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 11 buys, 0 sales | 2 buys, 29 sales |